IT-Mac 200 Capsule contains Itraconazole 200 mg, a broad-spectrum triazole antifungal agent indicated for the treatment of various systemic and superficial fungal infections. Itraconazole exerts its antifungal activity by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting membrane integrity and leading to fungal cell death. IT-Mac 200 is primarily prescribed for conditions such as blastomycosis, histoplasmosis, aspergillosis, onychomycosis, and other dermatophytic infections resistant to conventional therapy. The capsule formulation ensures optimal bioavailability when administered orally, with absorption enhanced by acidic gastric conditions. Dosage and duration of therapy should be tailored according to the severity and type of infection, patient response, and clinical guidelines. Caution is advised in patients with hepatic impairment, congestive heart failure, or those receiving concomitant medications metabolized via the cytochrome P450 system, due to potential drug interactions and hepatotoxicity risk. Regular monitoring of liver function tests and clinical status is recommended during prolonged therapy. IT-Mac 200 should be used under medical supervision, with adherence to prescribed dosing to maximize therapeutic efficacy and minimize adverse effects. It is contraindicated in patients with known hypersensitivity to itraconazole or other azole antifungals.